Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31590845 | 0.84 | ALOX15 (0.55) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL1287657 | 0.81 | TSHR (0.52) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL5668124 | 0.80 | TSHR (0.61) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL10598923 | 0.80 | TSHR (1.00) | TSHRALOX15CA2CA4CA5A | |
| Hydrochloric Acid SCHEMBL11507042 | 0.80 | ALOX15 (0.50) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL31590664 | 0.78 | TSHR (0.48) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL14335130 | 0.77 | TSHR (0.47) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL31590628 | 0.75 | TSHR (0.46) | TSHRALOX15CA2CA4CA5A | |
| Phenylphosphonic Acid SCHEMBL34998 | 0.75 | CA2 (1.00) | TSHRALOX15CA2CA4CA5A | |
| SCHEMBL191567 | 0.75 | CA2 (0.68) | TSHRALOX15CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-11-05 | — | — | US | disclosed |
| US-10420738-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-24 | — | — | US | disclosed |
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-03 | — | — | US | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160101107-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-14 | — | — | US | disclosed |
| US-20160101107-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-14 | — | — | US | disclosed |
| US-20160095869-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-07 | — | — | US | disclosed |
| US-20160095869-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-07 | — | — | US | disclosed |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-01-07 | — | — | US | disclosed |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-01-07 | — | — | US | disclosed |
| EP-2616444-B1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INST BIOCHEMII I BIOFIZYKI PAN (PL) | 2015-08-26 | — | — | EP | disclosed |
| US-20130303761-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2013-11-14 | — | — | US | disclosed |
| US-20130303761-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2013-11-14 | — | — | US | disclosed |
| WO-2012036573-A2 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TMEM120A | TSHR 2685/4885ALOX15 4466/4885CA2 2128/4885 |
| US-10420738-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TCOF1 | TSHR 2566/4885ALOX15 4631/4885CA2 2129/4885 |
| US-20160101107-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TCOF1 | TSHR 2566/4885ALOX15 4631/4885CA2 2129/4885 |
| US-20130303761-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TCOF1, ABCC2 | TSHR 2350/4885ALOX15 4660/4885CA2 2394/4885 |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TCOF1 | TSHR 2566/4885ALOX15 4631/4885CA2 2129/4885 |
| US-20160095869-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TMEM120A | TSHR 2685/4885ALOX15 4466/4885CA2 2128/4885 |
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TCOF1 | TSHR 2566/4885ALOX15 4631/4885CA2 2129/4885 |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TMEM120A | TSHR 2685/4885ALOX15 4466/4885CA2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.